Ishares Msci Spain ETF vs Cassava Sciences Inc — how do they compare? Ishares Msci Spain ETF trades at $57.76 (market cap $2.30B), while Cassava Sciences Inc trades at $0.84 (market cap $39.40M). The key difference: Ishares Msci Spain ETF is far larger — about 58.4× Cassava Sciences Inc's market cap, and Ishares Msci Spain ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and Cassava Sciences Inc for 37 Days on average.
| EWP | FLNA | |
|---|---|---|
Market Cap | $2.30B | $39.40M |
Volume | 845,747 | 759,018 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $4.64 |
52-Week Low | $48.33 | $0.68 |
Typical Hold Time | 40 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →